Literature DB >> 7496353

Ph positive acute lymphoblastic leukemia in adults: molecular and clinical studies.

G Specchia1, D Mininni, A Guerrasio, G Palumbo, D Pastore, V Liso.   

Abstract

Fifty-six patients with ALL were investigated for bcr involvement by PCR. Breakpoints were found in 15 patients (26.8%). There were no differences in clinical and hematologic features or the percentages of complete response (CR) between the Ph+ and Ph- cases. The duration of CR was 6 and 8 months, respectively. In 7/9 Ph1 relapsed ALL we observed increased expression of myeloid markers and 2/9 showed a switch of cytotype (Ly-->My). In none of the 13 Ph- relapsed ALL patients did we observe these findings. 7/15 of Ph+ cases expressed P190 and mRNA ela2 and 8/15 patients showed P210, with mRNA b3a2 in 5 and b2a2 in 3, respectively. The percentage of CR was 57% in the P190+ and 87% in the P210+ group. Investigation of more Ph1+ ALL cases treated with a uniform protocol should be performed in the future in order to determine whether any such biological and clinical differences exist.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496353     DOI: 10.3109/10428199509075301

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Yi-Fen Shi; Na Wang; Zi-Yang Huang; Rong-Rong Chen; Yi-Sha Huang; Yi-Yi Zhu; Chong-Yun Xing; Bin Liang; Kang Yu; Jian-Hua Feng
Journal:  Cancer Manag Res       Date:  2020-08-10       Impact factor: 3.989

2.  Immunophenotypes and outcome of Philadelphia chromosome-positive and -negative Thai adult acute lymphoblastic leukemia.

Authors:  Chirayu Udomsakdi-Auewarakul; Orathai Promsuwicha; Chintana Tocharoentanaphol; Chanya Munhketvit; Kovit Pattanapanyasat; Surapol Issaragrisil
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

3.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

4.  Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance.

Authors:  Tatsuaki Mizutani; Nina Neugebauer; Eva M Putz; Nadine Moritz; Olivia Simma; Eva Zebedin-Brandl; Dagmar Gotthardt; Wolfgang Warsch; Eva Eckelhart; Hans-Peter Kantner; Ulrich Kalinke; Stefan Lienenklaus; Siegfried Weiss; Birgit Strobl; Mathias Müller; Veronika Sexl; Dagmar Stoiber
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

5.  Four cases of chronic myelogenous leukemia in mixed phenotype blast phase at initial presentation mimicking mixed phenotype acute leukemia with t(9;22).

Authors:  Woojin Choi; Myungshin Kim; Jihyang Lim; Kyungja Han; Seok Lee; Jae Wook Lee; Nack Gyun Chung; Yonggoo Kim
Journal:  Ann Lab Med       Date:  2013-12-06       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.